Antibiotics and probiotics in treatment of inflammatory bowel disease

被引:73
作者
Gionchetti, Paolo [1 ]
Rizzello, Fernando [1 ]
Lammers, Karen M. [1 ]
Morselli, Claudia [1 ]
Sollazzi, Lucia [1 ]
Davies, Samuel [1 ]
Tambasco, Rosy [1 ]
Calabrese, Carlo [1 ]
Campieri, Massimo [1 ]
机构
[1] Univ Bologna, Dept Internal Med & Gastroenterol, Bologna, Italy
关键词
inflammatory bowel disease; intestinal microflora; antibiotics; probiotics;
D O I
10.3748/wjg.v12.i21.3306
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Many experimental and clinical observations suggest that intestinal microflora plays a potential role in the pathogenesis of inflammatory bowel disease (IBD). Manipulation of the luminal content using antibiotics or probiotics represents a potentially effective therapeutic option. The available studies do not support the use of antibiotics in ulcerative colitis (UC). Antibiotics are effective in treating septic complications of Crohn's disease (CD) but their use as a primary therapy is more controversial, although this approach is frequently and successfully adopted in clinical practice. There is evidence that probiotic therapy may be effective in the prevention and treatment of mild to moderate UC. In contrast, a lack of successful study data at present precludes the widespread use of probiotics in the treatment of CD. Both antibiotics and probiotics appear to play a beneficial role in the treatment and prevention of pouchitis and further trials are warranted to fully quantify their clinical efficacy. (C) 2006 The WJG Press. All rights reserved.
引用
收藏
页码:3306 / 3313
页数:8
相关论文
共 79 条
[21]   Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis [J].
Fiorucci, S ;
Distrutti, E ;
Mencarelli, A ;
Barbanti, M ;
Palazzini, E ;
Morelli, A .
DIGESTION, 2002, 66 (04) :246-256
[22]   Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Brigidi, P ;
Matteuzzi, D ;
Bazzocchi, G ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2000, 119 (02) :305-309
[23]   Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis [J].
Gionchetti, P ;
Rizzello, F ;
Venturi, A ;
Ugolini, F ;
Rossi, M ;
Brigidi, P ;
Johansson, R ;
Ferrieri, A ;
Poggioli, G ;
Campieri, M .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1999, 13 (06) :713-718
[24]   Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial [J].
Gionchetti, P ;
Rizzello, F ;
Helwig, U ;
Venturi, A ;
Lammers, KM ;
Brigidi, P ;
Vitali, B ;
Poggioli, G ;
Miglioli, M ;
Campieri, M .
GASTROENTEROLOGY, 2003, 124 (05) :1202-1209
[25]  
Gionchetti P, 1999, DIGEST DIS SCI, V44, P1220
[26]   Role of microecology in chronic inflammatory bowel diseases [J].
Guarner, F ;
Casellas, F ;
Borruel, N ;
Antolín, M ;
Videla, S ;
Vilaseca, J ;
Malagelada, JR .
EUROPEAN JOURNAL OF CLINICAL NUTRITION, 2002, 56 (Suppl 4) :S34-S38
[27]   Probiotics [J].
Guarner, F ;
Schaafsma, GJ .
INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, 1998, 39 (03) :237-238
[28]   Saccharomyces boulardii in maintenance treatment of Crohn's disease [J].
Guslandi, M ;
Mezzi, G ;
Sorghi, M ;
Testoni, PA .
DIGESTIVE DISEASES AND SCIENCES, 2000, 45 (07) :1462-1464
[29]   A pilot trial of Saccharomyces boulardii in ulcerative colitis [J].
Guslandi, M ;
Giollo, P ;
Testoni, PA .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2003, 15 (06) :697-698
[30]   Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice [J].
Hoentjen, F ;
Harmsen, HJM ;
Braat, H ;
Torrice, CD ;
Mann, BA ;
Sartor, RB ;
Dieleman, LA .
GUT, 2003, 52 (12) :1721-1727